Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L’Oreal Luxe Not Losing Steam In Asia; Consumer Biz Lifts On Garnier Momentum

Executive Summary

The French cosmetics giant continues to benefit from Chinese millennials with voracious luxury appetites, posting 14% like-for-like growth in its Luxe division for the fiscal 2019 first quarter. L’Oreal’s Consumer Products business is improving as well, with a return to growth in Western Europe, while North America continues to struggle.

You may also be interested in...



Estee Lauder Says Expected Q3 China Slowdown Didn’t Happen; More Financial News In Brief

Lauder again hikes its full-year net sales guidance after beating expectations with 11% reported growth in the fiscal 2019 third quarter. Coty reports on its turnaround progress, and Revlon points to optimistic improvements that drove Q1 constant-currency net revenue growth of 2.3%.

Unilever Q1: Aggressive M&A Paying Off; Oral Care Cited As Space To ‘Watch’

Anglo-Dutch firm’s prestige business, created in recent years through acquisitions such as Hourglass, Dermalogica and Kate Sommerville, grew by double digits in the first quarter. Oral care declined, but CEO Alan Jope is optimistic about the segment’s future.

Avon Joins Global #BeCrueltyFree Campaign Amid Natura Deal Talks

The turnaround-minded direct seller confirmed in late March that it was in discussions with Natura about a potential transaction. Natura prides itself on its cruelty-free status, and Avon increasingly seems like it could be a good fit in that regard.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel